Edition:
United Kingdom

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

0.84USD
23 Apr 2018
Change (% chg)

$-0.02 (-2.54%)
Prev Close
$0.86
Open
$0.86
Day's High
$0.86
Day's Low
$0.84
Volume
6,500
Avg. Vol
59,547
52-wk High
$1.34
52-wk Low
$0.80

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  BLRX.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -- -- --
ROI: -- -0.74 13.19
ROE: -- -2.80 15.00

BRIEF-BioLineRx Announces Notice of Allowance From USPTO for Patent Covering Immunotherapy for Treating Solid Tumors

* BIOLINERX ANNOUNCES NOTICE OF ALLOWANCE FROM USPTO FOR PATENT COVERING AGI-134 - A NOVEL IMMUNOTHERAPY FOR TREATING SOLID TUMORS

26 Mar 2018

BRIEF-Biolinerx Reports Year End 2017 Financial Results

* BIOLINE RX LTD - COMPANY HELD $49.5 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

06 Mar 2018

BRIEF-Biolinerx Announces Partial Monotherapy Results From Phase 2A Combat Study In Pancreatic Cancer

* BIOLINERX ANNOUNCES PARTIAL MONOTHERAPY RESULTS FROM PHASE 2A COMBAT STUDY IN PANCREATIC CANCER

17 Jan 2018

BRIEF-Bioline Rx Ltd Files For Mixed Shelf Of Up To $150 Million

* BIOLINE RX LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text (http://bit.ly/2lcDvcH) Further company coverage:

28 Dec 2017

InVivo to open crop input unit to outside investors

PARIS, Dec 19 French agricultural group InVivo said on Tuesday that it plans to raise 50 million euros ($59 million) for its Bioline division, which develops crop inputs such as seeds and pesticides, by bringing in outside investors.

19 Dec 2017

BRIEF-BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

* BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML

04 Dec 2017

BRIEF-BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​

* BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​ Source text for Eikon: Further company coverage:

21 Nov 2017

Earnings vs. Estimates

No consensus analysis data available.